Excel Medical Team
Excel Leadership
Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC
CEO, Excel Medical Clinical Trials
Chief Scientific Officer, Flourish Research; Clinical Affiliate Professor of Cardiology, Charles E. Schmidt College of Medicine, Florida Atlantic University
Dr. Seth J. Baum, a graduate of Columbia College and Columbia College of Physicians and Surgeons, completed training in Internal Medicine, Cardiology, Interventional Cardiology, and Electrophysiology.
Dr. Baum has practiced Preventive Cardiology and Clinical Lipidology since 2000. He is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology. Dr. Baum is a past President of the American Society for Preventive Cardiology (ASPC). He currently serves on both the ASPC and Family Heart Foundation Lp(a) Advisory Boards. He has published over 100 peer reviewed papers and abstracts as well as two books. In 2013, he was awarded Cleveland Heart Lab’s “Heart Award” for lifelong dedication to Preventive Medicine. In 2019, Dr. Baum received Mended Hearts’ biennial Dwight Emary Harken Award. Dr. Baum is the Founder and Chief Medical Officer of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials. He has served as Principal Investigator in over 100 clinical trials covering a broad band of disease states. Since 2022 he has been the Chief Scientific Officer for Flourish Research, a leading national clinical research company.
Dr. Baum is clinical affiliate professor of Cardioligy at FAU Medical School. He actively consults in Clinical Lipidology and Cardiovascular Disease Prevention and continues to offer lipoprotein apheresis for patients in southeast and central Florida.
Jean Scalea, MBS
Chief Operating Officer
Jean R. Scalea serves as the Chief Operating Officer at Excel Medical Clinical Trials. She has been an integral member of the company since its inception. She oversees and manages the company operations, including identifying opportunities for company growth, implementing business plans, managing budgets, and collaborating with the team to develop efficient policies and procedures.
Jean was previously the Acting President of an ophthalmic medical device company. With experience in domestic and international operations, and regulatory and clinical affairs, she served as the Company’s Official Correspondent to the FDA and the Study Director for multiple original Investigational Device Exemptions (IDE) and Investigational Testing Applications for Class III medical devices in both US and Canada. She created and successfully filed multiple annual and final reports to the FDA, supplemental Amendments to Premarket Approved (PMA) devices and devices under IDEs and obtained a 180-day PMA Supplement approval from the FDA for a device that is distributed in the US market today.
Jean earned her Master of Biomedical Sciences from The University of Medicine and Dentistry of New Jersey and BS from Rutgers University.
